Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting

Molecular Genetics and Metabolism

Volumn 99, Issue 1, 2010, Pages 90-97

  Sangar, Michelle Cook ^a   Anandatheerthavarada, Hindupur K ^a   Martin, Martha V ^b   Guengerich, F Peter ^b   Avadhani, Narayan G ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic variants; Human mitochondrial CYP2D6; Inter individual variations; Mitochondrial targeting signal

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450 2D6; MITOCHONDRIAL ENZYME; PROTEIN KINASE C;

ARTICLE; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE LOCUS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CYTOCHROME P-450 CYP2D6; EXONS; GENETIC VARIATION; HUMANS; LIVER; MICROSOMES; MITOCHONDRIA, LIVER; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN SORTING SIGNALS; PROTEIN TRANSPORT; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 71649115838     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.08.009     Document Type: Article

References (33)

1. Bertz R.J., and Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32 (1997) 210-258
2. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs. Arch. Pharmacol. 369 (2004) 23-37
3. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60 (1997) 284-295
4. Zanger U.M., Fischer J., Raimundo S., Stüven T., Evert B.O., Schwab M., and Eichelbaum M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 (2001) 573-585
5. Griese E.U., Zangar U.M., Brudermanns U., Gaedigk A., Mikus G., Morike K., Stüven T., and Eichelbaum M. Assessment of the predictive power of genotypes in the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8 (1998) 15-26
6. Zanger U.M., Turpeinen M., Klein K., and Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392 (2008) 1093-1108
7. Rau T., Wohlleben G., Wuttke H., Thuerauf N., Lunkenheimer J., Lanczik M., and Eschenhagen T. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther. 75 (2004) 386-393
8. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., and Flockhart D.A. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80 (2006) 61-74
9. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., Simon W., Eichelbaum M., and Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25 (2007) 5187-5193
10. Kirchheiner J., Heesch C., Bauer S., Meisel C., Seringer A., Goldammer M., Tzvetkov M., Meineke I., Roots I., and Brockmöller J. Impact of the ultrarapid metabolizer genotype of cytochrome P40 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76 (2004) 302-312
11. Tomalik-Scharte D., Lazar A., Fuhr U., and Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 8 (2008) 4-15
12. Sangar M.C., Anandatheerthavarada H.K., Tang W., Prabu S.K., Martin M.V., Dostalek M., Guengerich F.P., and Avadhani N.G. Human liver mitochondrial CYP2D6: individual variations and implications in drug metabolism. FEBS J. 276 (2009) 3440-3453
13. 2-terminal-processed microsomal protein to mitochondria: a novel pathway for the biogenesis of hepatic mitochondrial P450MT2. J. Cell Biol. 139 (1997) 589-599
14. Anandatheerthavarada H.K., Addya S., Dwivedi R.S., Biswas G., Mullick J., and Avadhani N.G. Localization of multiple forms of inducible cytochromes P450 in rat liver mitochondria: immunological characteristics and patterns of xenobiotic substrate metabolism. Arch. Biochem. Biophys. 339 (1997) 136-150
15. Anandatheerthavarada H.K., Biswas G., Mullick J., Sepuri N.B., Otvos L., Pain D., and Avadhani N.G. Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP-dependent phosphorylation at ser128. EMBO J. 18 (1999) 5494-5504
16. Bhagwat S.V., Biswas G., Anandatheerthavarada H.K., Addya S., Pandak W., and Avadhani N.G. Dual targeting property of the N-terminal signal sequence of P450 1A1. Targeting of heterologous proteins to endoplasmic reticulum and mitochondria. J. Biol. Chem. 274 (1999) 24014-24022
17. Robin M.A., Anandatheerthavarada H.K., Biswas G., Sepuri N.B., Gordon D.M., Pain D., and Avadhani N.G. Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J. Biol. Chem. 277 (2002) 40583-40593
18. Anandatheerthavarada H.K., Amuthan G., Biswas G., Robin M.A., Murali R., Waterman M.R., and Avadhani N.G. Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points. EMBO J. 20 (2001) 2394-2403
19. Robin M.A., Anandatheerthavarada H.K., Fang J.K., Cudic M., Otvos L., and Avadhani N.G. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N-terminus and requires mitochondrial specific electron transfer proteins for activity. J. Biol. Chem. 276 (2001) 24680-24689
20. Boopathi E., Anandatheerthavarada H.K., Bhagwat S.V., Biswas G., Fang J.K., and Avadhani N.G. Accumulation of mitochondrial P450MT2, NH(2)-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with β-naphthoflavone. A role in the metabolism of neuroactive drugs. J. Biol. Chem. 275 (2000) 34415-34423
21. Strauss W.M. Preparation of genomic DNA from mammalian tissue. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Current Protocols in Molecular Biology (1998), Wiley, New York (Chapter 2, Unit 2.2)
22. Koch J.A., and Waxman D.J. P450 phosphorylation in isolated hepatocytes and in vivo. Methods Enzymol. 206 (1991) 305-315
23. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin-Phenol reagent. J. Biol. Chem. 193 (1951) 265-275
24. Gasser S.M., Daum G., and Schatz G. Import of proteins into mitochondria. Energy-dependent uptake of precursors by isolated mitochondria. J. Biol. Chem. 257 (1982) 13034-13041
25. Bhat N.K., and Avadhani N.G. The transport and processing of carbamyl phosphate synthetase-I in mouse hepatic mitochondria. Biochem. Biophys. Res. Commun. 118 (1984) 514-522
26. Gough A.C., Miles J.C., Spurr N.K., Moss J.E., Gaedigk A., Eichelbaum M., and Wolf C.R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347 (1990) 773-776
27. Hanioka N., Kimura S., Meyer U.A., and Gonzalez F.J. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 - a base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 47 (1990) 994-1001
28. Kagimoto M., Heim M., Kagimoto K., Zeugin T., and Meyer U.A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265 (1990) 17209-17214
29. Rogan P.K., Svojanovski S., and Leeder J.S. Information theory-based analysis of CYP2C19, CYP2D6, CYP3A5 splicing mutations. Pharmacogenetics 13 (2003) 207-218
30. Blom N., Sicheritz-Ponten T., Gupta R., Gammeltoft S., and Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4 (2004) 1633-1649
31. Denson J., Wu Y., Yang W., and Zhang J. Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver. Biochem. Biophys. Res. Commun. 330 (2005) 498-504
32. Zhuge J., and Yu Y.N. Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue. World J. Gastroenterol. 10 (2005) 3356-3360
33. Rowland P., Blaney F.E., Smyth M.G., Jones J.J., Leydon V.R., Oxbrow A.K., Lewis C.J., Tennant M.G., Modi S., Eggleston D.S., Chenery R.J., and Bridges A.M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281 (2006) 7614-7622